Skp 2 Overexpression Is Highly Representative of Intrinsic Biological Aggressiveness and Independently Associatedwith Poor Prognosis in Primary LocalizedMyxofibrosarcomas
Hsuan-Ying Huang,Hong-Yo Kang,Chien-Feng Li,H. Eng,S. Chou,Ching‐Nan Lin,C. Hsiung
Abstract:Purpose: Two SCF ubiquitin ligase ^ related proteins, Skp2 and cyclin-dependent kinase subunit 1 (Cks1), are involved in posttranscriptional degradation of p27 tumor suppressor. We analyzed the prognostic utility of p27and its interacting cell cycle regulators inmyxofibrosarcomas. Experimental Design: Clinicopathologic features and tissue microarray ^ based immunohistochemical expression of p27, Skp2, Cks1, cyclin E, cyclin A, Ki-67, and minichromosomemaintenance protein 2 (Mcm2) were assessed in 70 primary myxofibrosarcomas and correlated with clinical outcomes. Skp2 mRNA expression and the relationship between Skp2 and p27 proteins were examined in six cases by semiquantitative reverse transcription-PCR and Western blotting, respectively. Results: High indices of Skp2 (z10%), cyclin A (z10%), and Mcm2 (z50%) were adverse prognosticators at theunivariate level. Furthermore, co-overexpressionof Skp2andcyclinA identified highly lethal cases in the entire cohort [P < 0.0001for disease-specific survival (DSS), P = 0.0004 for overall survival (OS)] and the lower-grade subset (Fe¤ de¤ ration Nationale des Centres de Lutte Contre le Cancer grade 1and 2; P = 0.0006 for DSS, P = 0.0093 for OS). In multivariate analyses, Skp2 overexpression overshadowed most intrinsic clinicopathologic factors and independently correlated with worse metastasis-free survival (P = 0.0012), DSS (P = 0.0234), and OS (P = 0.0056). Notably, positive margins independently predicted inferior local recurrence-free survival (P = 0.0012) and also negatively affected metastasis-free survival (P = 0.0471), DSS (P = 0.0152), and OS (P = 0.0173). Reverse transcription-PCR showed up-regulation of Skp2 mRNA in four cases andWestern blotting displayed a matched expression pattern of Skp2. Conclusions:Margin status and intrinsic property of myxofibrosarcomas both affect patient survival. Skp2 overexpression is highly representative of the biological aggressiveness ofmyxofibrosarcomas and plays an important prognostic role. Myxofibrosarcoma is a common soft-tissue sarcoma usually affecting the extremities of the elderly (1, 2). Histologically, it shows a broad spectrum of nuclear atypia, cellularity, and mitoses and is characterized clinically by increased metastases after relentless local recurrences (1, 2). Limited series analyzing primary myxofibrosarcomas provided inconsistent prognostic information about various clinicopathologic factors (1–4). For instance, it is challenging to precisely predict patient survival by histologic grading for myxofibrosarcomas without multivariate survival analyses. Huang et al. (1) had compared the utility of two-, threeand four-tier grading schemes for myxofibrosarcomas at the low-grade end. However, their prognostic values were all found insignificant as compared with other variables (1). The limitations of histologic evaluation underscore the need to identify molecular markers that can effectively predict clinical outcomes of this entity. During multistep carcinogenesis, sequential deregulation of multiple cell cycle regulators represents common modes of genetic alterations that promote progression in aggressive tumor subsets, thereby conferring an adverse effect on patient survival (5). p27 is a new tumor suppressor that specifically inhibits the activity of both cyclin E/CDK2 complex in G1-S transition and cyclin A/CDK2 complex in S phase to control cell cycle progression (6). Although reduced expression of p27 protein was shown to be highly associated with clinical Imaging, Diagnosis, Prognosis Authors’Affiliations: Departments of Pathology and Radiation Oncology and Graduate institute of Clinical Medical Science, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University, Kaohsiung, Taiwan; Department of Pathology, Chi-Mei FoundationMedical Center,Tainan,Taiwan; and Department of Pathology and Laboratory Medicine,Veterans General HospitalKaohsiung, Kaohsiung,Taiwan Received 7/11/05; revised10/2/05; accepted10/26/05. Grant support: National Science Council,Taiwan, grant NSC93-2320-B-182A011and Chang GungMemorial Hospital grant CMRPG83019. The costs of publication of this article were defrayed in part by the payment of page charges.This article must therefore be hereby marked advertisement in accordance with18 U.S.C. Section1734 solely to indicate this fact. Requests for reprints: Ching-Yeh Hsiung, Department of Radiation Oncology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University, 123, Ta-Pei Road, Niao-Sung, Kaohsiung County, Taiwan. Phone: 11-886-7-7317123-2537; Fax: 11-886-7-7333198; E-mail: a120600310@yahoo.com. F2006 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-05-1497 www.aacrjournals.org Clin Cancer Res 2006;12(2) January15, 2006 487 Research. on May 31, 2017. © 2006 American Association for Cancer clincancerres.aacrjournals.org Downloaded from aggressiveness in a variety of cancers (6–9), down-regulation of p27 mRNA was rarely observed in human malignancies (6). Instead, it becomes apparent that the loss of expression of p27 protein in malignant diseases resulted from enhanced ubiquitin-mediated proteolysis regulated by SCF-type ubiquitin E3 ligase complex (7, 8, 10–14). The substrate-recognition component of the latter complex is Skp2, a member of the F-box protein family, which peaks in abundance during S phase to target Thr-phosphorylated p27 for degradation (10, 11, 15). Recently, high Skp2 expression was also found predictive of poor prognosis in breast (12), prostate (13), kidney (7, 8), and head and neck cancers (10). Nevertheless, Skp2 did not correlate with low p27 in some malignancies (14, 16), implying that additional factors were implicated in p27 degradation or, alternatively, that Skp2 could possibly execute oncogenic function through p27-independent mechanisms. Recently, human cyclin-dependent kinase subunit 1 (Cks1) has been identified as a cofactor in the ubiquitination and degradation of p27, which confers an allosteric change in Skp2 to increase the affinity of SCF complex to phosphorylated p27 (17–19). The prognostic role of Cks1 has been exemplified in colorectal (18) and gastric (19) carcinomas in pilot studies, showing the association between Cks1 overexpression and adverse outcomes. To date, very few studies have addressed the prognostic utility of Skp2 or Cks1 in specific types of soft tissue sarcomas (14, 20). The proliferation of tumor cells is highly related to the rate of DNA synthesis and may provide objective prognostic information. The minichromosome maintenance proteins (Mcm), consisting of six members (Mcm2-7), is a family of highly conserved proteins, which form a hexameric complex for regulating eukaryotic DNA duplication (21). Their expression is seen during all phases of cell cycle and may represent the rate of cell proliferation (21). To assemble the prereplication complex, replication licensing factors, Cdt1 and Cdc6, are required in G1 phase to load Mcm proteins onto chromatin. This process is coined as ‘‘licensing,’’ which ensures that DNA replicates only once during each cell cycle (21–23). Interestingly, apart from p27, SCF complex was also found to polyubiquitinate Cdt1 protein for proteasome-mediated degradation (24). Accordingly, it is tempting to apply immunohistochemistry to explore how p27/Skp2 pathway is related to the members of Mcm proteins in human cancers, including sarcomas. Interestingly, a recent comparative genomic hybridization study on myxofibrosarcomas (25) reported high-level amplifications in chromosome 5p where the Skp2 gene is located. Although the prognostic values of p27and Skp2 had been individually reported for heterogeneous types of sarcomas (9, 14), no study has comprehensively elucidated the roles of ubiquitin-mediated proteolysis of p27 and its interacting proteins involving cell cycle regulation in myxofibrosarcomas. Therefore, the aims of this study were to specifically address the following questions about myxofibrosarcomas: (a) the expression status of p27, Skp2, Cks1, cyclin A, and cyclin E and two markers of cell proliferation, Ki-67 and Mcm2; and (b) the relative prognostic importance of clinicopathologic characteristics versus protein markers tested. Finally, we also examined Skp2 mRNA expression level by semiquantitative reverse transcription-PCR (RT-PCR) and the specificity and interaction of Skp2 and p27 proteins by Western blotting in six primary myxofibrosarcomas. Materials andMethods Patients and tumor material. Seventy patients with myxofibrosarcomas were retrospectively identified after pathologic review. They received primary surgical excision between 1985 and 2003 at three medical centers in Southern Taiwan, including Chang Gung Memorial Hospital (n = 42), Chi Mei Medical Center (n = 16), and Veteran General Hospital (n = 12). The diagnostic criteria were according to the latest WHO classification adapted from Mentzel’s series (2, 26), requiring at least 10% of myxoid component featuring curvilinear vessels to designate myxofibrosarcomas. H&E-stained slides and paraffin-embedded tissue blocks of primary lesions were available in all cases. Institutional review boards of the involved hospitals approved retrospective clinical data collection and procurement of archival and fresh tissues. None of the patients had received neoadjuvant radiation or chemotherapy before surgery. Postoperative adjuvant radiotherapy (n = 26) and/or chemotherapy (n = 14) was randomly given in a minor subset of high-grade or recurrent cases without a consistent guideline, which were therefore excluded from analysis. The histopathologic features evaluated included the margin status, depth, percentages of myxoid area and spontaneous necrosis, nuclear pleomorphism (slight/moderate versus prominent), and mitoses per 10 high-power fields (HPF). In addition, grading and staging of primary myxofibrosarcomas were determined according to the updated Fédération Nationale des Centres